Log In
BCIQ
Print this Print this
 

Lithobid, lithium carbonate

  Manage Alerts
Collapse Summary General Information
Company Hisamitsu Pharmaceutical Co. Inc.
DescriptionExtended-release lithium carbonate
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationBipolar disorder
Indication DetailsTreat bipolar disorder
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$12.0M

$11.0M

$1.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/01/2014

$12.0M

$11.0M

$1.0M

Get a free BioCentury trial today